03 October 2020: Clinical Research
Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension
Zirui Hao 1BCDE , Yue Sun 1BF , Yingzhen Wen 1BF , Lijuan Cui 1BF , Guiping Li 1DF , Yan Liu 2AG*DOI: 10.12659/MSM.925987
Med Sci Monit 2020; 26:e925987
Table 1 Comparison of patient baseline characteristics.
| Variables | With dapagliflozin (n=182) | Without dapagliflozin (n=304) | P |
|---|---|---|---|
| Age (years) | 43.7±13.3 | 41.1±14.6 | 0.03 |
| Female, n (%) | 55 (30.2) | 108 (35.5) | 0.01 |
| Duration of diabetes (years) | 3.6 (1.4–8.9) | 3.4 (1.2–8.2) | 0.14 |
| Duration of hypertension (years) | 6.8 (3.3–10.4) | 6.6 (3.1–9.9) | 0.71 |
| Office SBP (mmHg) | 143±20 | 144±21 | 0.82 |
| Office DBP (mmHg) | 86±17 | 85±16 | 0.77 |
| Heart rate (beat per min) | 74±16 | 75±17 | 0.53 |
| Body mass index (kg/m) | 24.2±6.3 | 24.9±6.5 | 0.008 |
| Obesity, n (%) | 58 (31.9) | 105 (34.6) | 0.02 |
| Smoking, n (%) | 70 (38.5) | 118 (38.8) | 0.26 |
| Hyperuricemia, n (%) | 63 (34.6) | 107 (35.2) | 0.32 |
| Dyslipidemia, n (%) | 78 (42.9) | 128 (42.1) | 0.95 |
| Atrial fibrillation, n (%) | 12 (6.6) | 25 (8.2) | 0.09 |
| Congestive heart failure, n (%) | 20 (10.9) | 31 (10.2) | 0.10 |
| Coronary heart disease, n (%) | 38 (20.9) | 66 (21.7) | 0.22 |
| Ischemic stroke/TIA, n (%) | 18 (9.9) | 31 (10.2) | 0.31 |
| Peripheral arterial disease, n (%) | 10 (5.5) | 19 (6.3) | 0.41 |
| Obstructive sleep apnea, n (%) | 23 (12.6) | 34 (11.2) | 0.61 |
| Total cholesterol (mmol/L) | 5.1±0.9 | 5.2±1.0 | 0.18 |
| Triglyceride (mmol/L) | 1.7 (0.8–2.6) | 1.9 (0.9–2.7) | 0.04 |
| Creatinine (umol/L) | 70.4±15.3 | 69.2±15.5 | 0.51 |
| eGFR (ml/min/1.73m2) | 80.8±15.4 | 79.6±14.8 | 0.22 |
| C-reactive protein (mg/dL) | 3.0±1.1 | 3.2±1.0 | 0.13 |
| SBP – systolic blood pressure; DBP – diastolic blood pressure; TIA – transient ischemic attack; eGFR – estimated glomerular filtration rate; * | |||